Saturday, November 19, 2022 6:16:04 PM
the market only rewards reality and at present the prospect of an influx of near-future cash. The reality is that even for GBML L with solid evidence after 2 days of trading we still sit at only one billion in MC. Apparently mr Market wants to see the prospect of cash influx (BO, approval, royalty sales, JV whatever), thats how the market for biotech works these days. You dont need to be a "Doctor" to make that simple observation.
DCVAX has NOT provided ANY final evidence it works for other cancer indications outside GBM until then the market and a BP buying NWBO will NOT value it as such.
If what you said would hold any merit then we would not sit at 1 billion MC WITH overwhelming evidence for GBM. But here you dream of valuations with no evidence or approval of the outcome of nonexisting trials.
But hey if you want to value NWBO at 100 billion based on GBM approval alone because perhaps all solid tumors, its your dreamworld I will stay in reality.
I thought you repeatedly said you are a seasoned investor? yet here you paint unrealistic pictures,
DCVAX has NOT provided ANY final evidence it works for other cancer indications outside GBM until then the market and a BP buying NWBO will NOT value it as such.
If what you said would hold any merit then we would not sit at 1 billion MC WITH overwhelming evidence for GBM. But here you dream of valuations with no evidence or approval of the outcome of nonexisting trials.
But hey if you want to value NWBO at 100 billion based on GBM approval alone because perhaps all solid tumors, its your dreamworld I will stay in reality.
I thought you repeatedly said you are a seasoned investor? yet here you paint unrealistic pictures,
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
